We have recently demonstrated that French Canadians bearing a mutation in the lipoprotein lipase (LPL) gene present an impaired lipoprotein-lipid profile characterized by small low-density lipoprotein (LDL) and high-density lipoprotein (HDL) particles compared with healthy subjects. It has also been documented that obesity has a significant impact on HDL and LDL particle sizes. OBJECTIVE: To examine the extent to which obesity modulates HDL and LDL particle sizes among carriers of mutations in the LPL gene. SUBJECTS: Analyses were carried out in 206 heterozygous carriers of the D9N mutation (N ¼ 118) or the P207L mutation (N ¼ 88). MEASUREMENTS: Lipoprotein particle sizes were measured on whole plasma by nondenaturing polyacrylamide gradient gel electrophoresis. RESULTS: In general, body mass index (BMI) and waist circumference were significant correlates of LDL and HDL particle sizes among heterozygous carriers of the P207L or D9N mutation in the LPL gene, with relatively similar associations among men and women. Multivariate analyses indicated that variations in waist circumference but not BMI were an independent predictor of variations in both HDL particle size (5.2%, P ¼ 0.0005) and LDL particle size (5.9%, P ¼ 0.01) in the entire group of heterozygotes for LPL mutation in a model that included the nature of the LPL mutation (D9N vs P207L), gender, age, cholesterol and plasma TG levels. Interestingly, there was a significant interaction between plasma TG levels and waist circumference or BMI in modulating HDL particle size. Indeed, an increased waist circumference or BMI was associated with a significant reduction in HDL particle size among subjects with plasma TG levels r3.5 mmol/l, but not among those with marked hypertriglyceridemia (TG levels 43.5 mmol/l). CONCLUSION: These results suggest that abdominal obesity, more so that overall obesity, is an important determinant of variations in LDL and HDL particle size among heterozygous carriers of mutations in the LPL gene, perhaps further contributing to modulate the risk of CHD in these individuals.
Introduction
Obesity, particularly abdominal obesity, is associated with an impaired plasma lipoprotein-lipid profile, which includes elevated triglyceride (TG) and apolipoprotein (apo) B concentrations and reduced high-density lipoprotein (HDL) cholesterol levels. 1 Obese patients are also characterized by reduced HDL particle size and by an increased proportion of small, dense low-density lipoprotein (LDL) particles. 2, 3 Population-based, prospective data from the Québec Cardiovascular Study have confirmed that the presence of small, dense LDL particles predicted subsequent coronary disease events, independent of variations in plasma TG and HDL cholesterol levels. 4, 5 The importance of HDL in the etiology of coronary heart disease (CHD) is also well established, increased plasma HDL cholesterol levels being associated with significant reductions in the risk of CHD. 6, 7 Studies have suggested that the cardioprotective properties of HDL may be attributed to the largest and less dense HDL 2 particles. 7 As a result of its pivotal role in the metabolism of circulating lipoproteins, lipoprotein lipase (LPL) certainly represents one of the key determinants modulating LDL and HDL particle sizes. 8 Indeed, LPL is the enzyme responsible for the hydrolysis of core TG in plasma chylomicrons and very low-density lipoproteins (VLDL), converting TG-rich lipoproteins to intermediate density lipoproteins (IDL) and LDL. 9 LPL also participates in the formation of HDL through this process. Thus, mutations in the LPL gene that alter the activity or mass of the resulting protein may modulate to various extents the metabolism of LDL and HDL particles. Among the numerous mutations responsible for primary LPL deficiency, three missence mutations of the LPL gene (G188E, P207L, D250N) are particularly frequent in the Saguenay-Lac-St-Jean region in the province of Québec in Canada. [10] [11] [12] The P207L mutation is associated with a carrier frequency of approximately 2% in this population. 13 Heterozygotes carrying these mutations in the LPL gene usually show a deteriorated lipid profile that includes elevated plasma TG levels and decreased HDL cholesterol concentrations. 9, 14 Other common structural variants in the LPL gene have been shown to have a more modest effect on LPL lipolytic function. 15 One of these mutations, the D9N mutation, has been associated with marginal to substantial increase in plasma TG levels and with an increased risk of coronary artery disease. [16] [17] [18] The D9N mutation underlies heterozygosity for LPL deficiency in 2-5% of Caucasians. 18, 19 We have recently demonstrated that individuals bearing a mutation in the LPL gene presented small LDL and HDL particles compared with healthy subjects and that carriers of the P207L mutation in the LPL gene were characterized by smaller LDL particles than carriers of the D9N mutation. 20, 21 However, the phenotypic expression of various mutations in the LPL gene is highly heterogeneous, depending on the nature of the mutation and on the presence of secondary factors such as obesity. The aim of the present study was therefore to examine the extent to which obesity as measured by the waist circumference and body mass index (BMI) modulates LDL and HDL particle sizes in familial heterozygous LPL deficiency.
Methods

Subject characteristics
A sample of 206 unrelated patients (109 men and 97 women) bearing a defect in the LPL gene were recruited at the Chicoutimi Hospital Lipid Clinic. All patients were participants in the Québec lipoprotein-lipase deficiency (LipD) Study and were from the Saguenay-Lac-St-Jean region, located in the northeastern part of the province of Québec (Canada). These subjects were heterozygous carriers of either the P207L (N ¼ 88) or the D9N (N ¼ 118) mutations in the LPL gene. Subjects' characteristics were previously described. 20, 21 Briefly, none of the premenopausal women were taking oral contraceptives. Menopausal status was assigned to women who did not have menses during the year that preceded the study. Among menopausal women under hormonal replacement therapy, approximately 89% were taking oral estrogen, 10% as patch and about 1% as gel. None of the subjects were using hypolipidaemic medication at time of evaluation. All participants gave their written consent to participate in this study, which received the approval from local ethic committees.
Mutation in the LPL gene
The P207L mutation in the LPL gene was detected by a mismatch-polymerase chain reaction (PCR) based approach followed by digestion with the restriction enzyme DdeI.
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The D9N mutation in the LPL gene was detected by standard PCR followed by digestion with the enzyme TaqI, as previously described. 19 Detection of the -93T/G mutation was performed as previously described.
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Plasma lipid-lipoprotein measurements Blood was drawn in EDTA tubes to a final concentration of 0.15% after a 12-h fast and plasma was isolated by centrifugation (2500 rpm at 41C, 15 min). Plasma total cholesterol, TG and HDL cholesterol levels were measured enzymatically. 24, 25 Total cholesterol was determined in plasma and HDL cholesterol was measured in the supernatant after precipitation of VLDL and LDL with dextran sulfate and magnesium chloride. 25 Cholesterol and TG levels in the LDL fraction isolated by sequential ultracentrifugations were also analyzed by standard enzymatic methods in a subgroup of subjects only. Plasma apoB levels were measured by the rocket immunoelectrophoresis method of Laurell as reported. 26 The apoE genotype was determined using the procedure described by Hixson and Vernier. 27 Determination of LDL and HDL particle diameter Nondenaturing 2-16% and 4-30% polyacrylamide gradient gel electrophoreses were used to determine LDL and HDL particle sizes, respectively, as previously described. 4,28 A mean particle size was computed by integrating the relative contribution of each subclass of LDL or HDL for a given subject. Analysis of pooled plasma standards revealed that measurement of particle size was highly reproducible with an interassay coefficient of variation o1% for LDL particle size 4 and o0.6 % for HDL particle size. 28 
Statistical analyses
Variables with a skewed distribution were log 10 -transformed for analysis, and are presented as geometric means in tables. Differences between P207L and D9N carriers were tested by the Student's t-test for continuous variables and by the test 29 The median value of the distribution of TG levels in the overall group of subjects (3.5 mmol/l) was used to define subjects with low vs high plasma TG levels. Multivariate analyses were conducted in the total group of subjects in order to identify the determinants of LDL and HDL particle sizes using general linear models. Inclusion of nonlipid lowering medication (diuretics and bblokers) in the model did not materially affect the association between LDL and HDL particle sizes and other study variables. Thus, only data without adjustment for medication use are presented. All statistical analyses were performed with the SAS software package (SAS Institute).
Results Table 1 compares the characteristics of the heterozygous carriers of the P207L vs the D9N mutation in the LPL gene. The D9N carriers were significantly older than subjects bearing the P207L mutation (P ¼ 0.003) while body weight, BMI and waist circumference were comparable between the two groups. The prevalence of smokers, type II diabetes, apoE genotype and the gender contribution were also similar between the two LPL mutation groups. It must be stressed that this cohort of LPL-deficient patients is not representative of the French-Canadian population. It is a highly biased population of dyslipidemic patients followed at the Chicoutimi Hospital Lipid Clinic. Among heterozygous carriers of the D9N mutation, 92.2% were also carriers of the -93T/G mutation in the LPL gene while only one heterozygote for the P207L mutation had the -93T/G mutation (1.1%, P ¼ 0.001). As shown previously, 20, 21 heterozygous carriers of the P207L mutation had a more atherogenic plasma lipoprotein-lipid profile compared with heterozygous carriers of the D9N mutation in the LPL gene. Figure 1 presents the univariate correlations between LDL and HDL particle sizes and BMI and waist circumference. Among carriers of the P207L mutation, there was a significant negative relation between BMI, waist circumference and LDL particle size (r ¼ À0.39, Po0.001 and r ¼ À0.36, Po0.001, respectively). On the other hand, the associations between BMI, waist circumference and LDL particle size were weaker and did not reach statistical significance among the D9N group (r ¼ À0.17, P ¼ 0.07 and r ¼ À0.13, P ¼ 0.10, respectively). Waist circumference was a significant univariate correlate of HDL particle size in the two groups of heterozygous LPL mutation carriers. However, there was a significant negative association between HDL particle size and BMI among carriers of the defective D9N mutation in the LPL gene (r ¼ À0.31, Po0.001) but not among the null P207L mutation carriers (r ¼ À0.17, P ¼ 0.10). Relatively similar associations were observed among men and women carriers of the P207L or D9N mutation in the LPL gene. These results suggest a degree of difference in the impact of obesity per se on LDL and HDL particle sizes depending upon the nature of the mutation in the LPL gene. Nevertheless, all associations indicated that individuals with larger waist circumference or BMI tended to be characterized by smaller LDL and HDL particles among this population of patients with partial LPL deficiency.
Abdominally Obesity and lipoprotein size in LPL deficiency IL Ruel et al 250.7710.5 Å , P ¼ 0.1) and HDL (82.574.6 vs 81.973.9 Å , P ¼ 0.4) particle sizes. Multivariate analyses were conducted to examine the extent to which variations in waist circumference and BMI predicted LDL and HDL particle sizes among the entire group of heterozygous LPL mutation carriers ( Table 2 ). The first model included as covariables the nature of the LPL mutation (D9N vs P207L), gender, age, log 10 -transformed cholesterol levels, plasma TG levels (below vs above 3.5 mmol/l), waist circumference (below vs above 102 cm for men and 88 cm for women) and the interaction between TG levels and waist circumference. Variations in waist circumference were an independent predictor of both LDL and HDL particle sizes (P ¼ 0.01 and 0.0005, respectively) in this multivariate model. BMI (below vs above 30 kg/m 2 ) did not predict LDL or HDL particle size in the multivariate analysis where it replaced waist circumference (model 2). Similar results were observed when the P207L and the D9N carriers were analyzed separately (not shown). Figure 2 illustrates the combined impact of plasma TG levels and waist circumference or BMI on LDL and HDL particle sizes. Although the impact of having an elevated waist circumference or BMI on LDL particle size was statistically attenuated among LPL mutation carriers with The GLM models included the following variables at entry: Model 1: LPL mutation (D9N vs P207L), gender, age, log 10 -transformed cholesterol and TG levels, waist circumference and the interaction between TG levels and waist circumference. Model 2 included all variables of the first model with the exception of waist girth, which was replaced by BMI. Waist circumference (below vs above 102 cm for men and 88 cm for women), BMI (below vs above 30 kg/m 2 ) and plasma TG levels (below and above 3.5 mmol/l) were treated as dichotomic variables in these analyses.
Obesity and lipoprotein size in LPL deficiency IL Ruel et al plasma TG levels 43.5 mmol/l, variations in plasma TG levels showed no interaction with waist circumference or BMI in modulating LDL particle size (top panel). On the other hand, an increased waist circumference or BMI was associated with a significant reduction in HDL particle size among subjects with plasma TG levels r3.5 mmol/l, but not among those with plasma TG levels 43.5 mmol/l (P ¼ 0.03 for the plasma TG Â waist circumference interaction and P ¼ 0.05 for the plasma TG Â BMI interaction).
Discussion
In the present study, we have examined the extent to which indices of obesity, namely waist circumference and BMI, modulated LDL and HDL particle sizes among heterozygous carriers of mutations in the LPL gene. In general, the associations between anthropometric variables such as BMI and waist circumference and LDL and HDL particle sizes among the two groups of LPL-deficient subjects indicated that individuals with the largest waist circumference or BMI tended to be characterized by the smallest LDL and HDL particles. When LPL mutation carriers were divided into subgroups of abdominally obese and nonobese subjects (waist circumference below vs above 102 cm for men and 88 cm for women), LDL and HDL particles were significantly larger among nonobese patients carriers of mutations in the LPL gene than among abdominally obese individuals. However, no statistical difference was observed in LDL and HDL particle sizes between nonobese and obese subjects separated according to their BMI (below vs above 30 kg/m 2 ).
In addition, waist circumference was an independent predictor of both LDL and HDL particle sizes among the heterozygous carriers of mutations in the LPL gene while BMI was not. This suggest that a preferential accumulation of body fat in the abdominal area, over and above the effect of obesity per se, further contributes to variations in lipoprotein particle size among heterozygotes for mutations in the LPL Body Mass Index
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Figure 2 LDL and HDL particle sizes among LPL mutation carriers divided into subgroups of abdominally obese and nonobese subjects (waist circumference below vs above 102 cm for men and 88 cm for women or BMI below or above 30 kg/m 2 ) and TG levels (below and above 3.5 mmol/l). Actual LDL and HDL particle sizes values are presented in this figure but significance levels (P-values) were obtained after adjustment for age, sex and the nature of the mutation in the LPL gene (P207L vs D9N).
Obesity and lipoprotein size in LPL deficiency IL Ruel et al gene. 30 Our data also suggested that plasma TG levels and waist circumference or BMI interacted in modulating HDL particle size. Indeed, increased waist circumference or BMI was associated with a significant reduction in HDL particle size among subjects with plasma TG levels r3.5 mmol/l, but not among heterozygotes for LPL deficiency with marked hypertriglyceridemia. It has been reported that obese patients are characterized by an unfavorable plasma-lipid profile that includes elevated TG concentrations, reduced HDL particle size and increased small, dense LDL particles. 2, 3 As in obese patients without primary dyslipidemia, we found that obesity as reflected by increased waist circumference was associated with an increased proportion of small LDL and HDL particles among carriers of mutations in the LPL gene. It has also been suggested that abdominal obesity per se may be a major cause of insulin resistance as a result of excess lipolysis of portally drained visceral adipose tissue, causing an increased flux of free fatty acids to the liver and an overproduction of hepatic TG-rich lipoproteins. 31 The resulting hypertriglyceridemia promotes the transfer of TG to LDL and HDL through the action of lipid transfer proteins. TG-enriched LDL and HDL can then be subjected to further lipolysis by hepatic lipase (HL), leading to the formation of small, dense LDL and HDL particles. 21, 32 Among carriers of a mutation in the LPL gene, the concomitant presence of a dyslipidemic state and of obesity may have led to the formation of smaller LDL and HDL particles through such mechanisms. Data from Després et al 33 suggested that abdominal obesity was also associated with reduced LPL activity and increased HL activity, two factors that may contribute to worsen the dyslipidemic state of obese carriers of a mutation in the LPL gene. Thus, partial LPL activity in these mutation carriers is probably not sufficient to keep levels of atherogenic TG-rich lipoproteins within normal limits when adverse influences such as that of obesity, particularly abdominal obesity, exert additional stress on the lipid transport system. Our results further suggested that the impact of obesity as measured by the waist circumference on LDL and HDL particle sizes was independent of the nature of the mutation in the LPL gene since waist circumference was an independent predictor of both LDL and HDL particle sizes among carriers of the null P207L mutation as well as in carriers of the defective D9N mutation in the LPL gene (not shown).
In the present study, abdominal obesity among carriers of mutations in the LPL gene had an effect on both LDL and HDL particle sizes that was also independent of TG levels. However, a marked hypertriglyceridemic state tended to attenuate the impact of obesity on LDL and HDL particle sizes. Thus, the reduction in LDL and HDL particle size among carriers of a LPL mutation with plasma TG levels 43.5 mmol/l may be attributable to a greater extent to the marked hypertriglyceridemic state rather than to obesity per se. As mentioned previously, hypertriglyceridemia plays a determinant role in promoting the formation of small LDL and HDL particles and patients with increased TG levels will generally be characterized by small LDL and HDL particles compared with patients having normal plasma TG concentrations 21, 32 . In the present study, nonobese subjects with TG levels 43.5 mmol/l were already characterized by small HDL particles, which may explain the absence of any further reduction in particle size in the presence of abdominal obesity.
Conclusion
In summary, univariate correlations suggested that individuals bearing a mutation in the LPL gene with a high waist circumference or BMI tended to be characterized by the smaller LDL and HDL particles. Multivariate analyses revealed that abdominal obesity, as measured by the waist circumference, contributed to further reduction in LDL and HDL particle sizes among heterozygotes for the P207L mutation in the LPL gene as well as in the D9N mutation carriers. Variations in BMI did not modulate the phenotypic expression of LDL and HDL particle sizes in both groups. These results suggest that abdominal obesity may further exacerbate the risk of atherosclerotic disease among heterozygotes for prevalent mutations in the LPL gene.
